Abstract
Hereditary ovarian carcinoma is heterogenous. There are at least three genetic variants, namely, hereditary site-specific ovarian carcinoma, hereditary breast/ovarian carcinoma syndrome, and Lynch syndrome II. Early age of onset characterizes these disorders. A crucial hallmark of these disorders is the integral association of extraovarian cancers, such as carcinoma of the endometrium and colon in Lynch syndrome II. We have described 24 pedigrees of ovarian cancer-prone families in order to depict the several differing heterogenous variants. Interest in hereditary ovarian cancer has increased remarkably, due in part to the fact that its surveillance has been wholly unsatisfactory, as have therapeutic measures. Prevention through prophylactic oophorectomy offers hope. However, there is a risk for extraovarian peritoneal serous papillary carcinoma, consonant with primary cancer of the ovary. This must be discussed with these at-risk patients. Until a biomarker of acceptable sensitivity and specificity is identified, the family history must remain the key to hereditary ovarian cancer diagnosis.
| Original language | English |
|---|---|
| Pages (from-to) | 161-183 |
| Number of pages | 23 |
| Journal | Cancer Genetics and Cytogenetics |
| Volume | 53 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1991 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cancer Research
- Genetics
- Molecular Biology
Cite this
Hereditary ovarian cancer. Pedigree studies, part II. / Lynch, Henry T.; Conway, Theresa; Lynch, Jane.
In: Cancer Genetics and Cytogenetics, Vol. 53, No. 2, 1991, p. 161-183.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hereditary ovarian cancer. Pedigree studies, part II
AU - Lynch, Henry T.
AU - Conway, Theresa
AU - Lynch, Jane
PY - 1991
Y1 - 1991
N2 - Hereditary ovarian carcinoma is heterogenous. There are at least three genetic variants, namely, hereditary site-specific ovarian carcinoma, hereditary breast/ovarian carcinoma syndrome, and Lynch syndrome II. Early age of onset characterizes these disorders. A crucial hallmark of these disorders is the integral association of extraovarian cancers, such as carcinoma of the endometrium and colon in Lynch syndrome II. We have described 24 pedigrees of ovarian cancer-prone families in order to depict the several differing heterogenous variants. Interest in hereditary ovarian cancer has increased remarkably, due in part to the fact that its surveillance has been wholly unsatisfactory, as have therapeutic measures. Prevention through prophylactic oophorectomy offers hope. However, there is a risk for extraovarian peritoneal serous papillary carcinoma, consonant with primary cancer of the ovary. This must be discussed with these at-risk patients. Until a biomarker of acceptable sensitivity and specificity is identified, the family history must remain the key to hereditary ovarian cancer diagnosis.
AB - Hereditary ovarian carcinoma is heterogenous. There are at least three genetic variants, namely, hereditary site-specific ovarian carcinoma, hereditary breast/ovarian carcinoma syndrome, and Lynch syndrome II. Early age of onset characterizes these disorders. A crucial hallmark of these disorders is the integral association of extraovarian cancers, such as carcinoma of the endometrium and colon in Lynch syndrome II. We have described 24 pedigrees of ovarian cancer-prone families in order to depict the several differing heterogenous variants. Interest in hereditary ovarian cancer has increased remarkably, due in part to the fact that its surveillance has been wholly unsatisfactory, as have therapeutic measures. Prevention through prophylactic oophorectomy offers hope. However, there is a risk for extraovarian peritoneal serous papillary carcinoma, consonant with primary cancer of the ovary. This must be discussed with these at-risk patients. Until a biomarker of acceptable sensitivity and specificity is identified, the family history must remain the key to hereditary ovarian cancer diagnosis.
UR - http://www.scopus.com/inward/record.url?scp=0025814797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025814797&partnerID=8YFLogxK
U2 - 10.1016/0165-4608(91)90094-B
DO - 10.1016/0165-4608(91)90094-B
M3 - Article
VL - 53
SP - 161
EP - 183
JO - Cancer Genetics and Cytogenetics
JF - Cancer Genetics and Cytogenetics
SN - 0165-4608
IS - 2
ER -